NasdaqGM:ETONPharmaceuticals
Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build
Eton Pharmaceuticals (ETON) came into focus after Chief Business Officer David Krempa exercised 10,000 Restricted Stock Units, converting them into common shares as part of a multi-year equity grant.
See our latest analysis for Eton Pharmaceuticals.
The recent equity grant vesting comes at a time when Eton Pharmaceuticals’ share price has moved to $37.51, with a 30-day share price return of 18.74% and a year-to-date share price return of 130.69%, while the 1-year total shareholder return...